Navigation Links
Mira Dx Licenses Triple Negative Breast Cancer Risk Variant from Yale University
Date:2/24/2011

NEW HAVEN, Conn., Feb. 24, 2011 /PRNewswire/ -- Mira Dx announced today that it has licensed technology from Yale University based on the acceptance of a pivotal breast cancer study in the January issue of the journal Cell Cycle. While numerous BRCA1 coding sequence mutations are associated with breast cancer risk, such mutations in BRCA1 account for less than 5% of breast cancer risk. The research identified microRNA disrupting variants in and around BRCA1 that are polymorphic in breast cancer populations. One key variant (rs8176318) shows significant cancer association for predicting the risk of developing triple negative breast cancer, especially for African American women.

It is estimated that last year in the US more than 207,090 women were diagnosed with breast cancer, and that 39,840 women died from the disease, according to the National Cancer Institute website. Triple negative breast cancer accounts for 15-20% of all breast cancers, and is the most deadly form of this disease.

"There is a real need for tools that can help women who have a family history of breast cancer to better understand their risk," said Martin Van Verhoef, President & CEO of Mira Dx. "We are pleased to continue our advancements in the field of miRNAs in cancer risk and plan to make this information available to women in 2011 in the form of a new triple negative breast cancer risk test." Verhoef continued, "We hope that cancer risk markers such as this marker will provide valuable information for the tens of thousands of women and families each year who are and may be affected by triple negative breast cancer."

Mira Dx was formed in February 2008 by researchers at Yale University to discover gene-based laboratory tests conducted on newly discovered genetic regulators called microRNAs (miRNAs). Mira Dx is applying miRNA discoveries to develop molecular diagnostics, which will provide individualized information on the likelihood of disease occurrence and response to certain types of therapy.

Mira Dx operates a CLIA lab out of New Haven, CT and currently runs a test to identify women at risk of epithelial ovarian cancer, PreOvar. Information on PreOvar and Mira Dx is available from the company's website, www.MiraDx.com.

About Mira DxMira Dx is a genomics company founded on research discovered at Yale University that is dedicated to the development and commercialization of novel microRNA-based tests for risk assessment and companion diagnostics. Our goal is to provide information that can help clinicians better understand cancer to better serve their patients, allowing earlier diagnosis, better management and ultimately higher cure rates.  For more information, please visit www.MiraDx.com.For more information, contact:Stephen Miller, Mira Dxsmiller@miradx.com, 203-789-9000 x206
'/>"/>

SOURCE Mira Dx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
2. Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
3. Duke Licenses ALPHADAS(R), Logos Technologies EDC System to Accelerate its Early Phase Clinical Trials
4. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
5. Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
6. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
7. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
8. The Quigley Corporation Licenses Naturally Derived Compound For Scar Improvement; License Requires Payments Totaling $1.1 Million To The Quigley Corporation Over A Five Year Period For Exclusive Ownership
9. PSKW & Associates LLC Acquires Triax Media, Licenses Triax to Subsidiary, Centricity Group
10. TenX Biopharma Licenses Zanolimumab From Genmab
11. Omnicare Clinical Research Licenses LiquentConnect to Create Added Value for Clients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/19/2017)... 2017   ZirMed Inc ., a recognized leader in ... it has been ranked #1 by its users for the ... 2017 User Survey. ZirMed was recognized as the top-ranked end-to-end ... medical centers over 200 beds and holds one of the ... survey history. ...
(Date:9/12/2017)... Sept. 12, 2017  Consumer reviews on the independent review site ... the number one company for hearing aids, ranking it higher than ... brands. ... #1 by Consumers For Hearing Aids ... Hearing is an online store that provides high performance, state-of-the-art, German-engineered ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally ... care, have expanded their existing home health joint venture through an agreement, effective ... operating a joint venture home health company with Asante, delivering clinically integrated care, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... has recently contributed a medical article to the newly revamped Cosmetic Town ... article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... one of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. ... awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at ...
Breaking Medicine News(10 mins):